[Federal Register Volume 60, Number 151 (Monday, August 7, 1995)]
[Notices]
[Page 40188]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-19417]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Prospective Grant of Exclusive License: Novel Neutrophil 
Chemotactic Factor, Cloned cDNA and Monoclonal Antibodies Thereto

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive world-wide license to practice the inventions embodied in 
a U.S. Patent Application 07/169,033 and corresponding foreign patent 
applications entitled, ``Novel Neutrophil Chemotactic Factor, Cloned 
cDNA and Monoclonal Antibodies Thereto'' to Chugai Pharmaceutical 
Company, Limited of Tokyo, Japan. The patent rights in these inventions 
have been assigned to the United States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    Activated monocytes/macrophages produce various mediators that 
cause inflammation. Among them are chemotactic factors which cause 
white blood cells to migrate into inflammatory sites where factors are 
released. Neutrophils, the dominant leukocytes attracted by the 
chemotactic factors play a critical role in inflammatory reactions. 
Rheumatoid arthritis, idiopathic pulmonary fibrosis and pathological 
inflammatory changes in a variety of other diseases are believed to be 
caused by neutrophils and/or their products. The present invention 
covers neutrophil chemotactic factor (interleukin-8, IL-8), a molecular 
clone containing the complete coding sequence for IL-8 and monoclonal 
antibodies to IL-8.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments and other materials relating to the contemplated licenses 
should be directed to: Raphe Kantor, Ph.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804. Telephone: (301) 496-7735 ext. 247; Facsimile: (301) 402-0220. A 
signed Confidentiality Agreement will be required to receive copies of 
the patent applications. Applications for a license in any field of use 
filed in response to this notice will be treated as objections to the 
grant of the contemplated licenses. Only written comments and/or 
applications for a license which are received by NIH on or before 
October 6, 1995, will be considered. Comments and objections submitted 
to this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: July 21, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-19417 Filed 8-4-95; 8:45 am]
BILLING CODE 4140-01-P